Literature DB >> 15723173

Confocal microscopy and biochemical analysis reveal spatial and functional separation between anandamide uptake and hydrolysis in human keratinocytes.

S Oddi1, M Bari, N Battista, D Barsacchi, I Cozzani, M Maccarrone.   

Abstract

The signaling activity of anandamide (AEA) is terminated by its uptake across the cellular membrane and subsequent intracellular hydrolysis by the fatty acid amide hydrolase (FAAH). To date, the existence of an AEA membrane transporter (AMT) independent of FAAH activity remains questionable, although it has been recently corroborated by pharmacological and genetic data. We performed confocal microscopy and biochemical analysis in human HaCaT keratinocytes, in order to study the cellular distribution of AMT and FAAH. We found that FAAH is intracellularly localized as a punctate staining partially overlapping with the endoplasmic reticulum. Consistently, subcellular fractionation and reconstitution of vesicles from membranes of different compartments demonstrated that FAAH activity was localized mainly in microsomal fractions, whereas AMT activity was almost exclusively in plasma membranes. These results provide the first morphological and biochemical evidence to support the view that transport and hydrolysis are two spatially and functionally distinct processes in AEA degradation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15723173     DOI: 10.1007/s00018-004-4446-8

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  33 in total

1.  Five-year clinical follow-up from the MISSION! Intervention Study: sirolimus-eluting stent versus bare metal stent implantation in patients with ST-segment elevation myocardial infarction, a randomised controlled trial.

Authors:  Helèn Boden; Bas L van der Hoeven; Su-San Liem; Jael Z Atary; Suzanne C Cannegieter; Douwe E Atsma; Marianne Bootsma; J Wouter Jukema; Katja Zeppenfeld; Pranobe V Oemrawsingh; Ernst E van der Wall; Martin J Schalij
Journal:  EuroIntervention       Date:  2012-01       Impact factor: 6.534

2.  Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study.

Authors:  Peter Wenaweser; Joost Daemen; Marcel Zwahlen; Ron van Domburg; Peter Jüni; Sophia Vaina; Gerrit Hellige; Keiichi Tsuchida; Cyrill Morger; Eric Boersma; Neville Kukreja; Bernhard Meier; Patrick W Serruys; Stephan Windecker
Journal:  J Am Coll Cardiol       Date:  2008-09-30       Impact factor: 24.094

3.  Very long-term clinical and angiographic outcomes after sirolimus- and paclitaxel-eluting stent placement for ST-elevation myocardial infarction: a propensity score-matched comparison.

Authors:  Takashi Miyamoto; Tetsuya Ishikawa; Yosuke Nakano; Makoto Mutoh
Journal:  Cardiovasc Interv Ther       Date:  2016-03-15

4.  Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial.

Authors:  Gregg W Stone; Bernhard Witzenbichler; Giulio Guagliumi; Jan Z Peruga; Bruce R Brodie; Dariusz Dudek; Ran Kornowski; Franz Hartmann; Bernard J Gersh; Stuart J Pocock; George Dangas; S Chiu Wong; Martin Fahy; Helen Parise; Roxana Mehran
Journal:  Lancet       Date:  2011-06-12       Impact factor: 79.321

5.  Very late stent thrombosis after primary percutaneous coronary intervention with bare-metal and drug-eluting stents for ST-segment elevation myocardial infarction: a 15-year single-center experience.

Authors:  Bruce Brodie; Yashashwi Pokharel; Nathan Fleishman; Adam Bensimhon; Grace Kissling; Charles Hansen; Sally Milks; Michael Cooper; Christopher McAlhany; Tom Stuckey
Journal:  JACC Cardiovasc Interv       Date:  2011-01       Impact factor: 11.195

6.  Long-term safety and effectiveness of drug-eluting stents compared to bare metal stents in ST elevation myocardial infarction: findings from the Guthrie Health Off-label Stent (GHOST) Registry.

Authors:  Sudhakar Sattur; Pam Orshaw; Judy Boura; Kishore J Harjai
Journal:  J Interv Cardiol       Date:  2012-02-10       Impact factor: 2.279

7.  Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51).

Authors:  Jessica L Mega; Eugene Braunwald; Sabina A Murphy; Alexei N Plotnikov; Paul Burton; Robert Gabor Kiss; Alexander Parkhomenko; Michal Tendera; Petr Widimsky; C Michael Gibson
Journal:  J Am Coll Cardiol       Date:  2013-03-07       Impact factor: 24.094

8.  Low-dose colchicine for secondary prevention of cardiovascular disease.

Authors:  Stefan M Nidorf; John W Eikelboom; Charley A Budgeon; Peter L Thompson
Journal:  J Am Coll Cardiol       Date:  2012-12-19       Impact factor: 24.094

9.  Drug-eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio ESpañol sobre TROmbosis de stents FArmacoactivos).

Authors:  José M de la Torre-Hernández; Fernando Alfonso; Felipe Hernández; Jaime Elizaga; Marcelo Sanmartin; Eduardo Pinar; Iñigo Lozano; Jose M Vazquez; Javier Botas; Armando Perez de Prado; Jose M Hernández; Juan Sanchis; Juan M Ruiz Nodar; Alfredo Gomez-Jaume; Mariano Larman; Jose A Diarte; Javier Rodríguez-Collado; Jose R Rumoroso; Jose R Lopez-Minguez; Josepa Mauri
Journal:  J Am Coll Cardiol       Date:  2008-03-11       Impact factor: 24.094

10.  Recurrent myocardial infarction after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.

Authors:  Wouter J Kikkert; Loes P Hoebers; Peter Damman; Krystien V V Lieve; Bimmer E P M Claessen; Marije M Vis; Jan Baan; Karel T Koch; Robbert J de Winter; Jan J Piek; Jan G P Tijssen; Jose P S Henriques
Journal:  Am J Cardiol       Date:  2013-10-03       Impact factor: 2.778

View more
  17 in total

1.  Pitfalls and solutions in assaying anandamide transport in cells.

Authors:  Sergio Oddi; Filomena Fezza; Giuseppina Catanzaro; Chiara De Simone; Mariangela Pucci; Daniele Piomelli; Alessandro Finazzi-Agrò; Mauro Maccarrone
Journal:  J Lipid Res       Date:  2010-05-06       Impact factor: 5.922

2.  Inhibition of the cellular uptake of anandamide by genistein and its analogue daidzein in cells with different levels of fatty acid amide hydrolase-driven uptake.

Authors:  L Thors; J Eriksson; C J Fowler
Journal:  Br J Pharmacol       Date:  2007-08-06       Impact factor: 8.739

Review 3.  Endocannabinoid liberation from neurons in transsynaptic signaling.

Authors:  David M Lovinger
Journal:  J Mol Neurosci       Date:  2007-09       Impact factor: 3.444

4.  The 'specific' tyrosine kinase inhibitor genistein inhibits the enzymic hydrolysis of anandamide: implications for anandamide uptake.

Authors:  L Thors; K Alajakku; C J Fowler
Journal:  Br J Pharmacol       Date:  2007-02-26       Impact factor: 8.739

5.  Identification of a high-affinity binding site involved in the transport of endocannabinoids.

Authors:  S A Moore; G G Nomikos; A K Dickason-Chesterfield; D A Schober; J M Schaus; B-P Ying; Y-C Xu; L Phebus; R M A Simmons; D Li; S Iyengar; C C Felder
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-28       Impact factor: 11.205

6.  Is there a temperature-dependent uptake of anandamide into cells?

Authors:  L Thors; C J Fowler
Journal:  Br J Pharmacol       Date:  2006-07-24       Impact factor: 8.739

Review 7.  Aspects of endocannabinoid signaling in periimplantation biology.

Authors:  Xiaofei Sun; Sudhansu K Dey
Journal:  Mol Cell Endocrinol       Date:  2008-01-18       Impact factor: 4.102

8.  Lipid droplets are novel sites of N-acylethanolamine inactivation by fatty acid amide hydrolase-2.

Authors:  Martin Kaczocha; Sherrye T Glaser; Janiper Chae; Deborah A Brown; Dale G Deutsch
Journal:  J Biol Chem       Date:  2009-11-19       Impact factor: 5.157

9.  Epigenetic control of skin differentiation genes by phytocannabinoids.

Authors:  Mariangela Pucci; Cinzia Rapino; Andrea Di Francesco; Enrico Dainese; Claudio D'Addario; Mauro Maccarrone
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

10.  Increased anandamide uptake by sensory neurons contributes to hyperalgesia in a model of cancer pain.

Authors:  Iryna A Khasabova; Michelle Holman; Tim Morse; Natalya Burlakova; Lia Coicou; Catherine Harding-Rose; Don A Simone; Virginia S Seybold
Journal:  Neurobiol Dis       Date:  2013-05-02       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.